Analyzing...
Loading company...
Procter & Gamble Health Ltd. engages in the manufacture and marketing of pharmaceuticals products. The company is headquartered in Mumbai, Maharashtra. The firm is engaged in the manufacturing and marketing of over-the-counter products, vitamins, minerals, and supplements products for a healthy lifestyle. The Company’s brands include Cosome, Evion, Neurobion, Seven Seas, Nasivion, Polybion, and Livogen. Cosome is a medicine which is used to help relieve dry coughs and related congestion symptoms. Evion is a Vitamin E capsules. The Evion range has different variants with different levels of Vitamin E, such as Evion 400, Evion 200, and Evion 600. Neurobion offers a range of neurotropic B-Vitamins which are a combination to help treat nerve damage and regenerate the nerves to relieve symptoms. Nasivion Classic Nasal Spray starts working on a blocked nose in 25 seconds. Polybion is a brand that helps with release and hence supports an active life.
No significant concerns identified
Nothing flagged for monitoring
“Operates in Pharmaceuticals — Formulations & API.”
₹1,408 Cr revenue.
COGS 25.9%, employees 15.8%.
| KPI | Company | Sector Median |
|---|---|---|
| ROE | 62.3%▲ | 10.3% |
| ROCE | 76.8%▲ | 13.7% |
| Net Margin | 22.9%▲ | 7.6% |
| EBITDA Margin | 33.3%▲ | 15.4% |
| Debt To Equity | 0.00x▼ | 0.15x |
Historical valuation data not available.
| (₹ Cr) | TTM | FY2025 | FY2024 | FY2024 | FY2023 | FY2023 | FY2022 | FY2022 |
|---|---|---|---|---|---|---|---|---|
| Revenue | ₹1,408 Cr +50.7% | ₹934 Cr -18.9% | ₹1,151 Cr 0.0% | ₹1,151 Cr -6.4% | ₹1,230 Cr 0.0% | ₹1,230 Cr +10.3% | ₹1,114 Cr 0.0% | ₹1,114 Cr |
| Other Income | ₹17 Cr +67.5% | ₹10 Cr -33.8% | ₹16 Cr 0.0% | ₹16 Cr -15.0% | ₹18 Cr 0.0% | ₹18 Cr +39.4% | ₹13 Cr 0.0% | ₹13 Cr |
| Total Income | ₹1,425 Cr +50.9% | ₹945 Cr -19.1% | ₹1,167 Cr 0.0% | ₹1,167 Cr -6.5% | ₹1,248 Cr 0.0% | ₹1,248 Cr +10.7% | ₹1,128 Cr 0.0% | ₹1,128 Cr |
| COGS | ₹365 Cr +39.1% | ₹263 Cr -20.6% | ₹331 Cr 0.0% | ₹331 Cr -8.6% | ₹362 Cr 0.0% | ₹362 Cr +6.5% | ₹340 Cr 0.0% | ₹340 Cr |
| ₹975 Cr +54.1% | ₹633 Cr -27.5% | ₹873 Cr 0.0% | ₹873 Cr -6.5% | ₹934 Cr 0.0% | ₹934 Cr +6.8% | ₹874 Cr 0.0% | ₹874 Cr | |
| Profit Before Tax | ₹450 Cr +44.4% | ₹312 Cr +14.0% | ₹273 Cr 0.0% | ₹273 Cr -13.0% | ₹314 Cr 0.0% | ₹314 Cr +24.0% | ₹253 Cr 0.0% | ₹253 Cr |
| ₹123 Cr +59.2% | ₹77 Cr +6.7% | ₹72 Cr 0.0% | ₹72 Cr -14.6% | ₹85 Cr 0.0% | ₹85 Cr +39.2% | ₹61 Cr 0.0% | ₹61 Cr | |
| Net Profit | ₹327 Cr +39.5% | ₹234 Cr +16.6% | ₹201 Cr 0.0% | ₹201 Cr -12.4% | ₹229 Cr 0.0% | ₹229 Cr +19.2% | ₹193 Cr 0.0% | ₹193 Cr |
| Other Comprehensive Income | (₹0.28 Cr) +89.3% | (₹3 Cr) ↓ Decline | ₹0.67 Cr 0.0% | ₹0.67 Cr ↑ Recovery | (₹2 Cr) 0.0% | (₹2 Cr) ↓ Decline | ₹0.70 Cr 0.0% | ₹0.70 Cr |
| EPS | ₹196.94 | ₹141.22 | ₹121.08 | ₹121.08 | ₹138.24 | ₹138.24 | ₹115.98 | ₹115.98 |
| Diluted Shares | ₹2 Cr | ₹2 Cr | ₹2 Cr | ₹2 Cr | ₹2 Cr | ₹2 Cr | ₹2 Cr | ₹2 Cr |
No related party data available for this company.
This section will be populated when data becomes available.
Procter & Gamble Health Limited has informed the Exchange regarding revision in date of Company s Annual General Meeting for the Financial Year 2025-26 and Record date for the purpose of AGM and Final...
Procter & Gamble Health Limited has informed the Exchange about Investor Presentation
Procter & Gamble Health Limited has informed the Exchange about Schedule of meet
Procter & Gamble Health Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015
Procter & Gamble Health Limited has informed the Exchange about General Updates
Procter & Gamble Health Limited has submitted to the Exchange, the financial results for the period ended December 31, 2025.
Procter & Gamble Health Limited has informed the Exchange regarding a Press release on unaudited Financial Results for the quarter ended December 31, 2025.
Procter & Gamble Health Limited has informed the Exchange that Record date for the purpose of Dividend is 12-Feb-2026.
Procter & Gamble Health Limited has informed the Exchange that Board of Directors at its meeting held on February 06, 2026, declared Interim Dividend of 160 per equity share (including a one-time spec...
Procter & Gamble Health Limited has informed the Exchange that Board of Directors at its meeting held on February 06, 2026, declared Interim Dividend of Rs. 160 per equity share (including a one-time ...
Procter & Gamble Health Limited has informed the Exchange about Certificate under SEBI (Depositories and Participants) Regulations, 2018
Procter & Gamble Health Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015
Procter & Gamble Health Limited has informed the Exchange about Appointment of Mr. Shashank Srowthy (11317956) as an Executive Director of the Company- via postal ballot
Procter & Gamble Health Limited has informed the Exchange regarding Proceedings of Postal Ballot. Further, the company has submitted the Exchange a copy of Srutinizers report.
Procter & Gamble Health Limited has informed the Exchange regarding a press release dated November 05, 2025, titled "Press release for the quarter ended September 30, 2025".
Disclaimer · The Stock Filter is an information platform, not a SEBI-registered investment adviser. All data, scores, and narratives are generated from public filings and AI analysis — they do not constitute investment advice, recommendations, or endorsements. Always consult a qualified financial adviser before making investment decisions. Past performance does not guarantee future results.